Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors.

@article{Kuhn2009TargetedIO,
  title={Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors.},
  author={Deborah J. Kuhn and Sally Anne Hunsucker and Qing Chen and Peter Michael Voorhees and Marian Orlowski and Robert Z. Orlowski},
  journal={Blood},
  year={2009},
  volume={113 19},
  pages={4667-76}
}
Proteasome inhibition is a validated strategy for therapy of multiple myeloma, but this disease remains challenging as relapses are common, and often associated with increasing chemoresistance. Moreover, nonspecific proteasome inhibitors such as bortezomib can induce peripheral neuropathy and other toxicities that may compromise the ability to deliver therapy at full doses, thereby decreasing efficacy. One novel approach may be to target the immunoproteasome, a proteasomal variant found… CONTINUE READING
79 Citations
63 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 79 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 63 references

Similar Papers

Loading similar papers…